De Pauw I - Search Results

1

Prognostic implications of cellular senescence in resected non-small cell lung cancer.

Domen A, Deben C, De Pauw I, Hermans C, Lambrechts H, Verswyvel J, Siozopoulou V, Pauwels P, Demaria M, van de Wiel M, Janssens A, Hendriks JMH, Van Schil P, Vermorken JB, Vandamme T, Prenen H, Peeters M, Lardon F, Wouters A. Domen A, et al. Among authors: de pauw i. Transl Lung Cancer Res. 2022 Aug;11(8):1526-1539. doi: 10.21037/tlcr-22-192. Transl Lung Cancer Res. 2022. PMID: 36090630 Free PMC article.

2

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.

Boeckx C, Van den Bossche J, De Pauw I, Peeters M, Lardon F, Baay M, Wouters A. Boeckx C, et al. Among authors: de pauw i. BMC Res Notes. 2015 Jun 2;8:203. doi: 10.1186/s13104-015-1197-6. BMC Res Notes. 2015. PMID: 26032726 Free PMC article.

3

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.

Van den Bossche J, Lardon F, Deschoolmeester V, De Pauw I, Vermorken JB, Specenier P, Pauwels P, Peeters M, Wouters A. Van den Bossche J, et al. Among authors: de pauw i. Med Res Rev. 2016 Jul;36(4):749-86. doi: 10.1002/med.21392. Epub 2016 May 3. Med Res Rev. 2016. PMID: 27140825 Review.

4

Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.

De Pauw I, Wouters A, Van den Bossche J, Peeters M, Pauwels P, Deschoolmeester V, Vermorken JB, Lardon F. De Pauw I, et al. Pharmacol Ther. 2016 Oct;166:71-83. doi: 10.1016/j.pharmthera.2016.06.014. Epub 2016 Jun 29. Pharmacol Ther. 2016. PMID: 27373506 Review.

5

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.

Van den Bossche J, Deben C, Op de Beeck K, Deschoolmeester V, Hermans C, De Pauw I, Jacobs J, Van Schil P, Vermorken JB, Pauwels P, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Among authors: de pauw i. J Cancer. 2017 May 12;8(8):1441-1452. doi: 10.7150/jca.18455. eCollection 2017. J Cancer. 2017. PMID: 28638459 Free PMC article.

6

Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.

De Pauw I, Wouters A, Van den Bossche J, Deschoolmeester V, Baysal H, Pauwels P, Peeters M, Vermorken JB, Lardon F. De Pauw I, et al. Cancer Biother Radiopharm. 2017 Sep;32(7):229-238. Cancer Biother Radiopharm. 2017. PMID: 28910149

7

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. De Pauw I, et al. Mol Oncol. 2018 Jun;12(6):830-854. doi: 10.1002/1878-0261.12197. Epub 2018 May 1. Mol Oncol. 2018. PMID: 29603584 Free PMC article.

8

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.

De Pauw I, Lardon F, Van den Bossche J, Baysal H, Pauwels P, Peeters M, Vermorken JB, Wouters A. De Pauw I, et al. Cancers (Basel). 2019 Jan 15;11(1):98. doi: 10.3390/cancers11010098. Cancers (Basel). 2019. PMID: 30650638 Free PMC article.

9

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.

Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Among authors: de pauw i. Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5. Mol Oncol. 2019. PMID: 30859681 Free PMC article.

10

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.

Van den Bossche J, Domen A, Peeters M, Deben C, De Pauw I, Jacobs J, De Bruycker S, Specenier P, Pauwels P, Vermorken JB, Lardon F, Wouters A. Van den Bossche J, et al. Among authors: de pauw i. Cancers (Basel). 2019 Nov 28;11(12):1893. doi: 10.3390/cancers11121893. Cancers (Basel). 2019. PMID: 31795121 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page